Company intelligence / Profile preview

PD-1 Acquisition Group

Hayward, California, United States

Ownership: Private
Development stage: Other

Overview

PD-1 Acquisition Group was a specialized biotechnology entity formed to manage and develop specific immunotherapy assets, most notably the PD-1 inhibitor mDX-401 (also known as GLS-010 or zimberelimab). The company was primarily involved in the early-stage clinical development of this monoclonal antibody for the treatment of advanced solid tumors. Its operations were closely tied to the licensing and development agreements between Arcus Biosciences and WuXi Biologics. The entity served as a transitional vehicle for the asset's rights before broader commercial and clinical integration by its partners.

Therapeutic areas: Oncology
Modalities: Monoclonal antibody
Industry: Biotech

Partnerships

Arcus BiosciencesWuXi BiologicsHarbour BioMed

Beyond the preview

Go deeper on PD-1 Acquisition Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PD-1 Acquisition Group.

Explore the full profile